October 27, 2026

Third Quarter 2026 Earnings Presentation

MIRION

Disclaimer

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "anticipate", "believe", "continue", "could", "estimate", "expect", "hope", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "should", "strive", "seeks", "would", "will", "understand" and similar words are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward looking. These forward-looking statements include but are not limited to, statements regarding our future operating results, financial position and guidance, our backlog and order potential, our business strategy and plans, our objectives for future operations, macroeconomic trends including the trends in cancer care, nuclear power and small modular reactor industries, foreign exchange, interest rate and inflation expectations and any future mergers, acquisitions, divestitures and strategic investments, including the completion and integration of previously completed transactions. There are a significant number of factors that could cause actual results to differ materially from statements made in this Presentation, including changes in domestic and foreign business, market, economic, financial, political and legal conditions, including related to matters affecting Russia, the relationship between the United States and China, conflict, hostilities or geopolitical instability in the Middle East (including the U.S.-Israel-Iran conflict), potential tariffs, sanctions, export controls, trade restrictions or other trade and supply chain disruptions, and risks of slowing economic growth or economic recession in the United States and globally; developments in the government budgets (defense and non-defense) in the United States and other countries, including budget reductions, sequestration, implementation of spending limits or changes in budgetary priorities, delays in the government budget process, a U.S. government shutdown or the U.S. government's failure to raise the debt ceiling; risks related to the public's perception of nuclear radiation and nuclear technologies; risks related to the continued growth of our end markets and timing of customer capital spending, procurement timing and project schedules; our ability to win new customers and retain existing customers; our ability to realize sales expected from our backlog of orders and contracts; risks related to governmental contracts; our ability to mitigate risks associated with long-term fixed price contracts, including risks related to inflation; risks related to information technology system failures or other disruptions or cybersecurity, data security or other security threats, including risks related to the implementation and enhancement of information systems and emerging technologies such as artificial intelligence; our ability to manage our supply chain or difficulties with third-party manufacturers; risks related to competition; our ability to manage disruptions of, or changes in, our independent sales representatives, distributors and original equipment manufacturers; our ability to realize the expected benefit from strategic transactions, such as acquisitions, divestitures, investments and partnerships, including any synergies, or internal restructuring and improvement efforts; our ability to issue debt, equity or equity-linked securities in the future; risks related to changes in tax law and ongoing tax audits; risks related to future legislation and regulation both in the United States and abroad; risks related to the costs or liabilities associated with product liability claims; risks related to the uncertainty of legal claims, litigation, arbitration and similar proceedings; our ability to attract, train and retain key members of our leadership team and other qualified personnel; risks related to the adequacy of our insurance coverage; risks related to the global scope of our operations, including operations in international and emerging markets; risks related to our exposure to fluctuations in foreign currency exchange rates, interest rates and inflation, including the impact on our debt service costs; our ability to comply with various laws and regulations and the costs associated with legal compliance; risks related to the outcome of any litigation, government and regulatory proceedings, investigations and inquiries; risks related to our ability to protect or enforce our proprietary rights on which our business depends or third-party intellectual property infringement claims; liabilities associated with environmental, health and safety matters; our ability to predict our future operational results; and the effects of health epidemics, pandemics and similar outbreaks may have on our business, results of operations or financial condition. Further information on risks, uncertainties and other factors that could affect our financial results are included in the filings we make with the United States Securities and Exchange Commission (the "SEC") from time to time, including under Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations in our most recent Annual Report on Form 10-K, and in our subsequently filed Quarterly Reports on Form 10-Q.

You should not rely on these forward-looking statements, as actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of such risks and uncertainties. All forward-looking statements in this Presentation are based on information available to us as of the date hereof, and we do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

Non-GAAP Financial Measures

In addition to our results determined in accordance with GAAP, we believe non-GAAP measures are useful in evaluating our operating performance, including organic revenues, adjusted EBITDA, adjusted EBITDA margin, adjusted net income, adjusted EPS, adjusted free cash flow, adjusted free cash flow conversion, and net leverage. We use this non-GAAP financial information to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. See the footnotes on the slides where these measures are discussed and the Non-GAAP reconciliations in the Appendix for a description of these non-GAAP financial measures and reconciliations to the most directly comparable GAAP financial measures. Additionally, forward-looking non-GAAP financial measures are presented on a non-GAAP basis without reconciliations of such forward-looking non-GAAP measures due to the inherent difficulty in projecting and quantifying the various adjusting items necessary for such reconciliations, such as stock-based compensation expense, amortization and depreciation expense, merger and acquisition activity and purchase accounting adjustments, that have not yet occurred, are out of Mirion's control or cannot be reasonably predicted. Accordingly, a reconciliation for our guidance organic revenue growth, adjusted EBITDA, adjusted earnings per share, adjusted free cash flow, adjusted free cash flow conversion, and net leverage is not available without unreasonable effort.

Industry and Market Data

In this presentation, we rely on and refer to information and statistics regarding market participants in the sectors in which Mirion competes and other industry data. We obtained this information and statistics from third-party sources, including reports by market research firms and company filings. Mirion has not independently verified the data obtained from these sources and cannot assure you of the data's accuracy or completeness.

Operating Metrics

This presentation contains certain operating metrics that our management uses to help us evaluate our business, identify trends affecting our business, formulate business plans and make strategic decisions, including orders. See the Appendix to this presentation for our definitions of such metrics.

Mirion

Q3 Key Takeaways

Delivering strong quarterly orders

+62% Q3 orders growth; +105% Nuclear Power end-market (both ex. M&A[1])

$140M of large opportunities awarded in Q3[2]

Strong conversion of backlog to revenue

+6.5% Q3 organic revenue growth

Expect mid-to-high teens organic revenue growth in Q4

Revising full year 2026 guidance

Increasing revenue guidance, reflecting higher backlog conversion

Net leverage expected to improve to ~2.6x by year-end[3]

Year-over-year growth numbers reflect comparison vs. Q3'25
1 Excludes July results from Certrec acquisition (closed July 31, 2025) and the entirety of the December 2025 Paragon acquisition.
2 Part of the large opportunity order pipeline previously disclosed; excludes China de-booking.
3 Assuming no Q4 share repurchases, M&A activity, or capital raises.

Strong Quarterly Orders Performance

Orders Performance Underlines Strong Demand Across Both Segments



KEY TAKEAWAYS:

3rd Quarter 2026

2x Nuclear Power end-market growth driven by strong new build and installed base activity

Strong Labs & Research and **Defense & Diversifieds** orders performance

All three Medical end markets contributing to orders growth; RTQA the biggest driver

Orders figures on an 'as reported' basis.
1 Certrec acquisition closed on July 31, 2025; Nuclear & Safety segment orders excludes July since Certrec was not part of Mirion in July 2025.
2 M&A includes the full Q3 impact from the Paragon acquisition and July Certrec orders. The Certrec acquisition closed on July 31, 2025 and the Paragon acquisition closed on December 1, 2025.

Positive Trend in Order Development

Organic Orders Growth Takes Another Step Higher

Trailing Twelve Month Order Growth, excluding M&A

$ millions



+37%

TTM order growth, excl. M&A

***Installed base** largest contribution to $ growth*

*Primarily reflects **Nuclear Power end-market growth***

Orders figures on an 'as reported' basis.
1 Paragon acquisition closed in December 2025. This is the third full quarter of Paragon being included in Mirion's financial and operational results.

Three Waves of Installed Base Nuclear Customer Demand

All Three Waves Materializing

1 CATCH-UP CAPITAL SPENDING

US Operating Fleet Capex per MWh[1]



2 LIFE-EXTENSION & POWER UPRATES

+890 MW[2] — Google Constellation

+433 MW[3] — VISTRA / U.S. Department of Energy

+190 MW[4] — amazon Constellation

+1.5 GW *targeted from recent announcements*

***96%** of U.S. reactors have been approved for **20-year life** extensions; corresponding investment work underway*

3 DIGITAL TRANSFORMATION

Installed Base Reactor Protection System Upgrade

- Part of existing reactor fleet's **digital upgrades**
- Installation beginning **November 2026** on first operating unit
- Follow-on units present **future digital upgrade opportunities**

1. August 2026 NEI report.
2. October 6, 2026 Constellation Energy press release.
3. October 5, 2026 United States Department of Energy press release.
4. September 30, 2026 Constellation Energy press release.

Backlog Dynamic

Sizeable Increase in Organic Conversion of Backlog

Expected Annual Backlog Conversion Trend[1]

$ millions



1 Total consolidated backlog view

Revenue Visibility from Backlog

Backlog Shows Improved Revenue Visibility vs. Prior Years



Confidence in FY'26 Performance

YTD performance + Q4'26 backlog reinforces full year guidance

Medical Segment is Largely 'Book & Bill'

Remaining revenue to achieve largely reflects intra-quarter Medical segment business

PeAks Revenue

Paragon revenue stream that does not appear in backlog (additive to our coverage dynamics)

1 FY'25 Adjusted Revenue excludes M&A (Paragon & Certrec) because both were not part of the YTD'25 backlog as of September 30, 2025.
2 Q4'25 backlog adjusted to exclude Certrec backlog conversion.
3 Revenue range reflects 2026 total revenue growth guidance.

Q3 Performance Highlights

$277.8M
Q3'26 Revenue

+6.5% organic vs. Q3'25;
+24.5% total; organic growth inflecting higher

$64.8M
Q3'26 Adj. EBITDA

+23.7% vs. Q3'25;
Largely driven by the Paragon acquisition, Nuclear Power end-market, and RTQA

$56M
Q3'26 shares repurchased

~3.6 million shares repurchased in Q3'26;
Completed $100 million repurchase program; introduced a new $250 million repurchase program *($235 million remaining)*



$47M Q3 Adj. FCF Generation
$107M or 58% conversion YTD Sep'26; 2x vs. YTD Sep'25

Excellent Q3 Orders
Growth across all end-markets in both segments

For a reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures, please see the Appendix.

2026 Large Opportunity Pipeline[1]

No YTD Large Opportunity Pipeline Awards Lost

Q1	Q2	Q3	Q4
Small Modular Reactors *First portion*	**Small Modular Reactors** *Second portion*	**European Operating Fleet** *EDF-based reactors*	*~$125 million of incremental opportunity still available in '26*
Radioactive Waste *First portion*	**Radioactive Waste** *Second portion; more to come*	**Labs & Research** *U.S. DoE-related*	
Operating Fleet Reactors *Safety-critical qualification*	**Small Modular Reactors** *First portion; more to come*	**China New Build De-booking[2]** *Booked in 2019*	
Radiation Cameras *RTQA Medical Order*		**Labs & Research** *U.S. DoE-related*	
		Nuclear New Build *Critical I&C*	
$53M	**$51M**	**$140M** *$122M less China de-booking*	**~$125M** *targeted for Q4'26*

1 Large opportunity pipeline projects are $10 million or more.
2 Previously disclosed in July 2026.

Growing Nuclear Power Momentum

Remain Confident in our Double-digit Organic Revenue Growth Projection

Nuclear Power End-market

+105%

Order Growth

excl. M&A[1] Q3'26 vs. Q3'25

+108% excluding FX
+134% excluding Chinese de-booking

$18M

SMR-related Orders[2]

+$1M Q3'26 vs. Q3'25

$83M YTD SMR-related orders[2]
+216% YTD'26 vs. YTD'25

+14%

Org. Revenue Growth

excl. FX & M&A[1] Q3'26 vs. Q3'25

+13% including FX

1 Excludes July results from Certrec acquisition (closed July 31, 2025) and the entirety of the December 2025 Paragon acquisition.
2 Updated compared to the original version to show total SMR-related orders, including M&A.

Mirion

Third Quarter Ended September 30, 2026

Revenue

$ millions | % percentage

%	Q3'26 vs. Q3'25
Organic	*+6.5%*
Acquisition	*+18.6%*
FX	*(0.6%)*
Total	***+24.5%***



Adjusted EBITDA and Margin[1]

$ millions | % percentage



Adjusted EBITDA Margin:

Q3'25	Q3'26
23.5%	*23.3%*

Adjusted diluted EPS[2]

$ cents

$0.11 *per share* — *includes stock-based compensation; similar comparison to Q3'26 Adjusted diluted EPS;*



For a reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures, please see the Appendix.
References to Q3 2025 and Q3 2026 are to the three months ended September 30, 2025 and 2026, respectively.
1 Adjusted EBITDA Margin calculated as Adjusted EBITDA divided by Revenue.
2 Q1'26 is the initial quarter that we are including stock-based compensation in the Adjusted EPS calculation. Note, Q3'25 is excluding stock-based compensation.

Mirion Nuclear & Safety

Third Quarter Ended September 30, 2026

Revenue

$ millions | % percentage

%	Q3'26 vs. Q3'25
Organic	*+6.3%*
Acquisition	*+28.7%*
FX	*(0.8%)*
Total	***+34.2%***



Adjusted EBITDA and Margin[1]

$ millions | % percentage



KEY TAKEAWAYS:

3rd Quarter 2026

Paragon revenue growth[2]
- *+12% vs Q3'25*
- *+22% vs YTD Sep'25*

+14% Nuclear Power end-market organic revenue driven by installed base and SMR growth

Adj. EBITDA margin decline as expected; driven by Paragon acquisition dilution, mix, and lower '25 incentive compensation

For a reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures, please see the Appendix.
References to Q3 2025 and Q3 2026 are to the three months ended September 30, 2025 and 2026, respectively.
1 Adjusted EBITDA Margin calculated as Adjusted EBITDA divided by Revenue.
2 Paragon financial performance reflects unaudited condensed consolidated financial statements

Mirion Medical

Third Quarter Ended September 30, 2026

Revenue

$ millions | % percentage

%	Q3'26 vs. Q3'25
Organic	*+6.7%*
Acquisition	*n/a*
FX	*0.0%*
Total	***+6.7%***

Adjusted EBITDA and Margin[1]

$ millions | % percentage



Adjusted EBITDA Margin:

Q3'25	Q3'26
35.9%	*37.8%*

KEY TAKEAWAYS:

3rd Quarter 2026

RTQA the largest driver of organic revenue growth, driven by continued OEM business performance

All three end markets contributing to organic revenue growth

Expanding margin performance driven by RTQA end market

For a reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures, please see the Appendix.
References to Q3 2025 and Q3 2026 are to the three months ended September 30, 2025 and 2026, respectively.
1 Adjusted EBITDA Margin calculated as Adjusted EBITDA divided by Revenue.

Adjusted Free Cash Flow

Structural Business Improvements Driving Greater Cash Generation

Adjusted Free Cash Flow & Conversion[1]

$ millions | % adj. EBITDA percentage



POSITIVE Q3'26 NET WORKING CAPITAL

Productivity metrics improved; Q4 NWC expected to be a source of cash

IMPROVING CASH TAXES

Lower cash taxes expected vs. 2025; better than initial guidance (see appendix)

LOW COST OF DEBT

2.8% expected full year; Efficient structure of convertible notes and re-priced TLB

For a reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures, please see the Appendix.
References to Q3 2025 and Q3 2026 are to the three months ended September 30, 2025 and 2026, respectively.
1 Adjusted Free Cash Flow conversion is calculated as Adjusted Free Cash Flow divided by Adjusted EBITDA.

Revising Guidance

Reflects Better Visibility to Full Year Performance

Change versus prior guidance:

- *Increased*
- *Tightened*
- *Reduced*

FY 2026 Guidance[1]

TOTAL REVENUE GROWTH

- **~24 – 25%**

Includes FX and acquisition-related impacts

ORGANIC REVENUE GROWTH

- **~7 – 8%**

MSD+ for Q4'26 Medical segment; High teens-plus for Q4'26 Nuclear & Safety segment

ADJUSTED EBITDA
Margin %

- **~$285 – $292M**
- ~24.7% – 25.2%

~(150) bps headwind from AI and Paragon

ADJUSTED FCF
Adjusted FCF Conversion % of Adjusted EBITDA

- **~$170 – $185M**
- 60% – 63%

ADJUSTED EARNINGS PER SHARE[2]

- **~$0.50 – $0.54**

per share

ANNUALIZED FOREIGN EXCHANGE SENSITIVITY[3]

+/- $3.5M
Revenue for every .01 Δ

+/- $1M
Adjusted EBITDA for every .01 Δ

1 2026 guidance includes an assumed fourth quarter foreign exchange rate of 1.12 Euro-to-USD,
2 Includes interest expense savings from convertible notes and refinanced Term Loan B; interest income from incremental cash on the balance sheet; additional earnings from acquisitions; stock-based compensation.
3 Foreign exchange sensitivities are based on Euro exchange rates.

Appendix

Expanding Backlog Reflects Orders Momentum

Attributing to Accelerated Revenue Growth



Improving Revenue Visibility from Backlog

Q3'26 backlog shows improving revenue visibility vs. prior years

Nuclear Power Dominated

63% of backlog related to the Nuclear Power end-market

Installed Base Leading the Way

Q3'26 Installed Base backlog (excl. M&A) of $326M, +55% YoY

Backlog figures on an as reported basis. Total backlog figures include acquisitions of Certrec, Oncospace, and Paragon Energy Solutions.

Organic Growth

Performance and Trends

MIRION

7 – 8%

'26E ORGANIC REVENUE GROWTH

Driven by Nuclear Power

NUCLEAR & SAFETY

END MARKET	NUCLEAR & SAFETY	NUCLEAR POWER	LABS & RESEARCH	DEFENSE & DIVERSIFIED INDUSTRIALS
2025 Organic Growth	MSD	DD	Neg HSD	LSD
2026E Organic Growth	HSD+ (Previously HSD)	DD	LSD (Previously FLAT)	MSD
2025 & 2026E COMMENTARY & TRENDS		• **2025:** New build and installed base driving double-digit growth; SMR accelerating • **2026E:** Growing momentum in installed base and SMRs	• **2025:** Negatively impacted by **(1)** delayed U.S. DoE and Chinese demand; **(2)** government shutdown; **(3)** and DOGE impacts. • **2026E:** Strong North America performance partially offset by weaker European performance	• **2025:** Double-digit industrials growth partially offset by a tough comparable of European civil defense revenue in 2024 • **2026E:** Accelerated defense revenue expected; tough comparable in diversified industrials

MEDICAL

END MARKET	MEDICAL	RADIATION THERAPY QUALITY ASSURANCE (RTQA)	NUCLEAR MEDICINE	DOSIMETRY
2025 Organic Growth	LSD	Neg (Previously DD)	DD	LSD
2026E Organic Growth	MSD	HSD+	MSD	Neg
2025 & 2026E COMMENTARY & TRENDS		• **2025:** Hardware headwinds in N. America, China, and Japan; partially offset by software tailwinds • **2026E:** Increased revenue from OEM sector; continued software platform growth; U.S. hardware growth	• **2025:** Hardware growth in the U.S. and RoW supported by expansion of clinic growth • **2026E:** Reduced hardware growth due to destocking; good order momentum in software	• **2025:** Continued adoption of InstadoseVUE®; timing headwind earlier in 2025 • **2026E:** Less hardware volume than expected; MSD service revenue growth

CANCER CARE

Non-GAAP Reconciliations

Adjusted Free Cash Flow and Net Leverage

($ millions)	YTD Q3'23	YTD Q3'24	YTD Q3'25	YTD Q3'26
Net cash provided by operating activities	**$28.2**	**$38.3**	**$70.3**	**$136.6**
Purchases of PPE and badges	(25.2)	(37.1)	(26.3)	(31.8)
Proceeds from derivative contracts	3.2	3.8	2.9	1.3
Cash used for non-operating expenses	6.1	6.9	6.2	1.4
Adjusted Free Cash Flow	**$12.3**	**$11.9**	**$53.1**	**$107.5**
Ending cash balance	$101	$134	$933	$409
Debt from first lien term loan	695	695	450	450
Convertible Note	-	-	775	775
Net Debt	**$594**	**$561**	**$266**	**$816**
LTM Adjusted EBITDA	176	195	220	262
LTM Adjusted EBITDA Contribution from M&A	-	-	3	4
LTM Adjusted EBITDA Plus M&A Contribution	**$176**	**$195**	**$223**	**$266**
Net Leverage *Total Net Debt / M&A Adjusted EBITDA*	**3.4x**	**2.9x**	**1.3x**	**3.1x**

2.8x excluding opportunistic share repurchases

- **Net Working Capital:** Use of cash YTD. Source of cash in Q4'26. Approximately flat net working capital impact expected for the full year 2026.
- **Net Interest Expense:** Reflects **(1)** reduced interest expense from lower Term Loan B principal partially offset by two convertible notes; and **(2)** higher interest income from elevated cash held from October 2025 capital raise to fund the December 2025 acquisition of Paragon.
- **Net Leverage:** ~2.6x expected by year-end[1]; in-line with our long-term net leverage target.

1 Assuming no Q4 share repurchases, M&A activity, or capital raises.

Modeling Assumptions

Supporting 2026 Guidance

Amortization: *(pre any incremental M&A)*
~$118M; *includes ~$25M associated with Paragon*

Interest Expense:
$450M SOFR + 2.00% for the '32 Term Loan B;
$400M 0.25% '30 convert notes; **$375M** 0% '31 convert notes

Capex:
~$50M

Net Working Capital:
flat; *productivity metrics improving; offset by project timing*

Cash Taxes:
~$25M

Stock-based Compensation:
~$25M

Effective Tax Rate:
~25 - 26%

Foreign Exchange Rate *(EUR-to-USD)*:
1.12; *fourth quarter 2026 assumption*

Basic Share Count:
~243M shares; *YE ~240M, assuming no incremental buybacks*

Diluted Share Count:
~272M shares; *includes convertible notes*

Eleven Quarter Segment Reconciliation

Nuclear & Safety

($ in millions)	3Q 2026	2Q 2026	1Q 2026	4Q 2025	3Q 2025	2Q 2025	1Q 2025	4Q 2024	3Q 2024	2Q 2024	1Q 2024
Revenue	**$ 194.0**	**$ 186.2**	**$ 185.5**	**$ 194.9**	**$ 144.6**	**$ 141.7**	**$ 133.4**	**$ 168.8**	**$ 132.7**	**$ 133.9**	**$ 125.8**
YoY % Growth - Total	*34.2 %*	*31.4 %*	*39.1 %*	*15.5 %*	*9.0 %*	*5.8 %*	*6.0 %*	*13.2 %*	*8.4 %*	*3.7 %*	*8.7 %*
YoY % Growth - Organic	*6.3 %*	*2.3 %*	*2.6 %*	*3.1 %*	*4.4 %*	*2.9 %*	*7.6 %*	*13.9 %*	*7.8 %*	*4.1 %*	*8.4 %*
YoY % Growth - Acquisitions	*28.7 %*	*28.1 %*	*31.6 %*	*7.6 %*	*1.8 %*	*— %*	*— %*	*— %*	*— %*	*— %*	*— %*
YoY % Growth - FX	*(0.8)%*	*1.0 %*	*4.8 %*	*4.8 %*	*2.8 %*	*2.9 %*	*(1.6)%*	*(0.7)%*	*0.6 %*	*(0.4)%*	*0.3 %*
Income from Operations	**$ 25.9**	**$ 26.0**	**$ 20.9**	**$ 39.1**	**$ 21.3**	**$ 19.0**	**$ 21.7**	**$ 33.1**	**$ 14.7**	**$ 18.5**	**$ 12.6**
Amortization	18.9	19.2	19.6	15.4	14.3	13.7	13.7	13.7	17.1	17.3	17.8
Depreciation	3.7	3.7	4.7	4.0	3.6	3.6	3.3	3.5	2.5	2.4	2.4
Stock compensation	0.8	1.0	0.7	0.9	0.7	0.3	0.5	0.5	0.5	0.4	0.4
Cost of revenues impact from inventory valuation purchase accounting	(0.3)	0.8	0.8	—	—	—	—	—	—	—	—
Non-operating expenses	0.9	0.2	0.1	0.4	0.7	1.0	—	1.7	—	0.4	—
Other income/expense	(0.1)	0.1	—	0.2	—	0.3	—	0.3	0.1	(0.1)	(0.1)
Adjusted EBITDA	**$ 49.8**	**$ 51.0**	**$ 46.8**	**$ 60.0**	**$ 40.6**	**$ 37.9**	**$ 39.2**	**$ 52.8**	**$ 34.9**	**$ 38.9**	**$ 33.1**
Income from operations margin	*13.4 %*	*14.0 %*	*11.3 %*	*20.1 %*	*14.7 %*	*13.4 %*	*16.3 %*	*19.6 %*	*11.1 %*	*13.8 %*	*10.0 %*
Adjusted EBITDA margin	*25.7 %*	*27.4 %*	*25.2 %*	*30.8 %*	*28.1 %*	*26.7 %*	*29.4 %*	*31.3 %*	*26.3 %*	*29.1 %*	*26.3 %*

Eleven Quarter Segment Reconciliation

Medical

($ in millions)	3Q 2026	2Q 2026	1Q 2026	4Q 2025	3Q 2025	2Q 2025	1Q 2025	4Q 2024	3Q 2024	2Q 2024	1Q 2024
Revenue	**$ 83.8**	**$ 80.6**	**$ 72.1**	**$ 82.5**	**$ 78.5**	**$ 81.2**	**$ 68.6**	**$ 85.5**	**$ 74.1**	**$ 73.2**	**$ 66.8**
YoY % Growth - Total	*6.5 %*	*(0.7)%*	*5.1 %*	*(3.5)%*	*5.9 %*	*10.9 %*	*2.7 %*	*5.2 %*	*7.7 %*	*7.7 %*	*0.6 %*
YoY % Growth - Organic	*6.7 %*	*(0.9)%*	*3.8 %*	*(4.8)%*	*5.2 %*	*10.1 %*	*3.0 %*	*3.7 %*	*3.2 %*	*2.6 %*	*0.6 %*
YoY % Growth - Acquisitions	*— %*	*— %*	*0.2 %*	*0.4 %*	*0.1 %*	*0.2 %*	*— %*	*1.5 %*	*4.4 %*	*5.2 %*	*(0.1)%*
YoY % Growth - FX	*(0.2)%*	*0.2 %*	*1.1 %*	*0.9 %*	*0.6 %*	*0.6 %*	*(0.3)%*	*— %*	*0.1 %*	*(0.1)%*	*0.1 %*
Income from Operations	**$ 15.6**	**$ 14.8**	**$ 7.8**	**$ 18.6**	**$ 10.7**	**$ 10.9**	**$ 6.7**	**$ 11.9**	**$ 4.0**	**$ 5.0**	**$ 1.4**
Amortization	10.5	10.8	11.4	10.7	11.4	11.5	11.7	12.2	13.0	13.7	13.7
Depreciation	4.9	4.8	4.8	5.4	5.3	4.8	4.7	5.1	5.5	4.9	4.8
Stock compensation	0.5	0.5	0.6	0.5	0.5	0.4	0.4	0.3	0.3	0.3	0.2
Non-operating expenses	0.4	0.3	—	(0.1)	0.6	2.6	—	3.8	2.4	1.4	0.4
Other income/expense	(0.2)	(0.1)	—	(0.2)	(0.3)	(0.1)	(0.3)	(0.1)	0.5	(0.2)	—
Adjusted EBITDA	**$ 31.7**	**$ 31.1**	**$ 24.6**	**$ 34.9**	**$ 28.2**	**$ 30.1**	**$ 23.2**	**$ 33.2**	**$ 25.7**	**$ 25.1**	**$ 20.5**
Income from operations margin	*18.6 %*	*18.4 %*	*10.8 %*	*22.5 %*	*13.6 %*	*13.4 %*	*9.8 %*	*13.9 %*	*5.4 %*	*6.8 %*	*2.0 %*
Adjusted EBITDA margin	*37.8 %*	*38.6 %*	*34.1 %*	*42.3 %*	*35.9 %*	*37.1 %*	*33.8 %*	*38.8 %*	*34.7 %*	*34.3 %*	*30.7 %*

Eleven Quarter Segment Reconciliation

Corporate & Other

($ in millions)	3Q 2026	2Q 2026	1Q 2026	4Q 2025	3Q 2025	2Q 2025	1Q 2025	4Q 2024	3Q 2024	2Q 2024	1Q 2024
Revenue	$ —	$ —	$ —	$ —	$ —	$ —	$ —	$ —	$ —	$ —	$ —
Income (Loss) from Operations	$ (24.3)	$ (22.9)	$ (25.0)	$ (32.2)	$ (24.6)	$ (20.0)	$ (19.7)	$ (16.0)	$ (20.3)	$ (21.2)	$ (18.9)
Amortization	—	—	—	—	—	—	—	—	—	—	—
Depreciation	0.2	0.3	0.3	0.1	0.2	0.3	0.3	0.1	0.4	0.2	0.1
Stock compensation	5.8	5.4	3.0	2.6	3.2	2.7	2.5	2.9	3.5	3.3	3.0
Non-operating expenses	1.8	0.2	4.8	12.1	4.1	0.4	1.2	(3.7)	1.7	2.5	1.7
Other income/expense	(0.2)	0.2	(0.2)	0.1	0.7	(0.2)	—	0.3	(0.2)	—	—
Adjusted EBITDA	$ (16.7)	$ (16.8)	$ (17.1)	$ (17.3)	$ (16.4)	$ (16.8)	$ (15.7)	$ (16.4)	$ (14.9)	$ (15.2)	$ (14.1)
Income from operations margin	*n.a*	*n.a*	*n.a*	*n.a*	*n.a*	*n.a*	*n.a*	*n.a*	*n.a*	*n.a*	*n.a*
Adjusted EBITDA margin	*n.a.*	*n.a.*	*n.a.*	*n.a.*	*n.a.*	*n.a.*	*n.a.*	*n.a.*	*n.a.*	*n.a.*	*n.a.*

Eleven Quarter Segment Reconciliation

Consolidated

($ in millions)	3Q 2026	2Q 2026	1Q 2026	4Q 2025	3Q 2025	2Q 2025	1Q 2025	4Q 2024	3Q 2024	2Q 2024	1Q 2024
Revenue	**$ 277.8**	**$ 266.8**	**$ 257.6**	**$ 277.4**	**$ 223.1**	**$ 222.9**	**$ 202.0**	**$ 254.3**	**$ 206.8**	**$ 207.1**	**$ 192.6**
YoY % Growth - Total	*24.5 %*	*19.7 %*	*27.5 %*	*9.1 %*	*7.9 %*	*7.6 %*	*4.9 %*	*10.4 %*	*8.2 %*	*5.0 %*	*5.8 %*
YoY % Growth - Organic	*6.5 %*	*1.2 %*	*3.0 %*	*0.5 %*	*4.7 %*	*5.4 %*	*6.0 %*	*10.3 %*	*6.1 %*	*3.6 %*	*5.5 %*
YoY % Growth - Acquisitions	*18.6 %*	*17.9 %*	*21.0 %*	*5.2 %*	*1.1 %*	*0.1 %*	*— %*	*0.5 %*	*1.6 %*	*1.8 %*	*— %*
YoY % Growth - FX	*(0.6)%*	*0.6 %*	*3.5 %*	*3.4 %*	*2.1 %*	*2.1 %*	*(1.1)%*	*(0.4)%*	*0.5 %*	*(0.4)%*	*0.3 %*
Income (Loss) from Operations	**$ 17.2**	**$ 17.9**	**$ 3.7**	**$ 25.5**	**$ 7.4**	**$ 9.9**	**$ 8.7**	**$ 29.0**	**$ (1.6)**	**$ 2.3**	**$ (4.9)**
Amortization	29.4	30.0	31.0	26.1	25.7	25.2	25.4	25.9	30.1	31.0	31.5
Depreciation	8.8	8.8	9.8	9.5	9.1	8.7	8.3	8.7	8.4	7.5	7.3
Stock compensation	7.1	6.9	4.3	4.0	4.4	3.4	3.4	3.7	4.3	4.0	3.6
accounting	(0.3)	0.8	0.8	—	—	—	—	—	—	—	—
Non-operating expenses	3.1	0.7	4.9	12.4	5.4	4.0	1.2	1.8	4.1	4.3	2.1
Other income/expense	(0.5)	0.2	(0.2)	0.1	0.4	—	(0.3)	0.5	0.4	(0.3)	(0.1)
Adjusted EBITDA	**$ 64.8**	**$ 65.3**	**$ 54.3**	**$ 77.6**	**$ 52.4**	**$ 51.2**	**$ 46.7**	**$ 69.6**	**$ 45.7**	**$ 48.8**	**$ 39.5**
Income from operations margin	*6.2 %*	*6.7 %*	*1.4 %*	*9.2 %*	*3.3 %*	*4.4 %*	*4.3 %*	*11.4 %*	*(0.8)%*	*1.1 %*	*(2.5)%*
Adjusted EBITDA margin	*23.3 %*	*24.5 %*	*21.1 %*	*28.0 %*	*23.5 %*	*23.0 %*	*23.1 %*	*27.4 %*	*22.1 %*	*23.6 %*	*20.5 %*

Non-GAAP Reconciliations

Consolidated – Income from Operations, Gross Profit & Adjusted EBITDA

($ in millions)	Three Months Ended September 30, 2026	Three Months Ended September 30, 2025
GAAP Net Income	**$ 7.8**	**$ 3.1**
Interest expense, net	5.7	6.7
Income tax expense (benefit) provision	3.1	(1.9)
Foreign currency loss (gain), net	0.1	(0.6)
Non-operating expenses	—	0.5
Other income/expense	0.5	(0.4)
Income from Operations	**$ 17.2**	**$ 7.4**
Amortization	$ 29.4	$ 25.7
Depreciation	8.8	9.1
Stock compensation expense	7.1	4.4
Cost of revenues impact from inventory valuation purchase accounting	(0.3)	—
Non-operating expenses	3.1	5.4
Other income/expense	(0.5)	0.4
Adjusted EBITDA	**$ 64.8**	**$ 52.4**
Gross Profit	**$ 131.5**	**$ 104.5**
Amortization	7.0	7.0
Depreciation	6.0	6.3
Cost of revenues impact from inventory valuation purchase accounting	(0.3)	—
Non-operating expenses	0.5	0.5
Adjusted Gross Profit	**$ 144.7**	**$ 118.3**
Adjusted Gross Profit margin	*52.1 %*	*53.0 %*

Non-GAAP Reconciliations

Adjusted Earnings per Share

($ in millions)	Three Months Ended September 30, 2026	Three Months Ended September 30, 2025
Net income attributable to Mirion Technologies, Inc. stockholders	**$ 7.4**	**$ 2.9**
Income attributable to noncontrolling interests	0.4	0.2
GAAP net income	**7.8**	**3.1**
Foreign currency loss (gain), net	0.1	(0.6)
Amortization of acquired intangibles	29.4	25.7
Stock-based compensation[1]	—	4.4
Cost of revenues impact from inventory valuation purchase accounting	(0.3)	—
Non-operating expenses	3.1	5.9
Tax impact of adjustments above	(8.4)	(7.1)
Adjusted net income	**$ 31.7**	**$ 31.4**
Weighted average common shares outstanding — basic and diluted	**242.390**	**224.583**
Dilutive potential common shares - stock-based awards	0.178	0.758
Dilutive potential common shares - convertible debt	30.321	30.321
Adjusted weighted average common shares — diluted	**272.889**	**255.662**
Net income per common share attributable to Mirion Technologies, Inc.	**$ 0.03**	**$ 0.01**
Adjusted EPS	**$ 0.12**	**$ 0.12**

1 The calculation for adjusted net income has been adjusted for the current period to include stock-based compensation.

Share Count

Details[1]

Share Description	Outstanding Securities as of 9/30/2026[2]	Outstanding Securities as of 12/31/2025[2]	Notes
Shares of Class A Common Stock, including Treasury Stock	**249,141,285**	**248,155,411**	▪ **Shares as of close of trading on the New York Stock Exchange (NYSE), including treasury stock purchased by Mirion**
Treasury Stock	(9,408,713)	(3,492,619)	▪ During the three months ended September 30, 2026, Mirion purchased 3.6 million shares of Class A common stock as part of a share repurchase program.
Outstanding Shares of Class A Common Stock	**239,732,572**	**244,662,792**	▪ **Outstanding shares as of close of trading on the New York Stock Exchange (NYSE), excluding treasury stock**
Shares of Class B Common Stock – Mirion Management[3]	5,759,555	5,869,555	▪ Shares of Class B common stock are owned by certain current and former members of Mirion's management team and are paired on a one-for-one basis with shares of Class B common stock of Mirion Intermediate Co, Inc. (the "paired interests"). Holders of the paired interests have the right to have their interests redeemed for, at the option of Mirion, shares of Class A common stock on a one-for-one-basis or cash based on a trailing stock price average.
Illustrative Total Shares Outstanding	**245,492,127**	**250,532,347**	
Convertible Notes	30,320,703	30,320,703	▪ During the year ended December 31, 2025, Mirion issued $775 million of notes potentially convertible to shares of Class A common stock (subject to the terms of the notes). The dilutive impact shown is based upon an initial conversion rate of 43.2751 shares per $1,000 principal amount of the May issuance ($400 million) and 34.6951 shares per $1,000 principal amount of the September issuance ($375 million).
Outstanding Equity Awards[4]	5,394,214	2,424,049	▪ Mirion had 0.8 million shares of restricted stock units, 2.1 million shares of performance stock units, and 2.5 million shares of performance stock options outstanding as of September 30, 2026. Additionally, Mirion had reserved an additional 43.2 million shares of Class A common stock for future equity awards issuance under its 2021 Omnibus Incentive Plan (subject to annual automatic increases) as of September 30, 2026.
Total Illustrative Fully Diluted Shares	**281,207,044**	**283,277,099**	

1 All data on this slide is as of September 30, 2026, or December 31, 2025, unless otherwise noted. All share numbers and dollar amounts are subject to adjustment for stock splits or other similar events.
2 This slide illustrates Mirion's outstanding and fully diluted shares based on certain assumptions set forth in the "Notes" column and is designed to be illustrative and provide investors with additional information only. Different assumptions will yield different results, and the actual number of our fully diluted shares in the future may differ significantly from those based on these assumptions. As a result, you should not rely on these forward-looking statements as predictions of future events. The information provided is not presented in accordance with Accounting Standards Codification (ASC) 260, Earnings Per Share (ASC 260) and does not represent a computation of weighted average shares nor are the numbers appropriate for calculating Basic or Diluted EPS under ASC 260.
3 The slide illustrates the assumption that all of the paired interests will be redeemed and exchanged for shares of Class A common stock.
4 The number of reserved shares are subject to automatic increases on the first day of each year in an amount equal to the lesser of (i) three percent (3%) of the outstanding shares of Class A common stock on the last day of the immediately preceding year, (ii) 9,976,164 shares of Class A common stock and (iii) such number of shares of Class A common stock as determined by Mirion Compensation Committee in its discretion.

Convertible Notes (Issued May and September 2025)

Illustrative Table of Potential Dilutive Impact of Convertible Notes due 2030 & 2031 and Capped Call Overlay

Following table illustrates the potential dilutive shares under (i) our $400M aggregate principal amount of convertible notes due 2030 and (ii) our $375M aggregate principal amount of convertible notes due 2031 (together, "the Notes") that would be included in the calculation of our future reported GAAP EPS assuming various hypothetical quarterly average market prices of our common stock (NYSE: MIR). The capped calls on each of the Notes are not included in the calculation of diluted GAAP EPS as they are anti-dilutive. The Notes are expected to have a dilutive effect on GAAP EPS while outstanding, but the actual dilution at maturity is reduced by the effects of our capped calls and upon an irrevocable election to net share settle the Notes

	GAAP EPS Impact[2]	Actual Dilution Impact[3]		
Hypothetical Quarterly Average Share Price[1]	Total Underlying Shares from Notes	Net Shares from the Notes	Net Shares Received from the Capped Calls	Total Expected Dilution at Maturity of the Notes
$15.00	30.32	-	-	-
$17.50	30.32	-	-	-
$20.00	30.32	-	-	-
$22.50	30.32	-	-	-
$25.00	30.32	1.31	(1.31)	-
$27.50	30.32	2.76	(2.76)	-
$30.00	30.32	4.49	(4.49)	-
$32.50	30.32	6.47	(6.47)	-
$35.00	30.32	8.18	(8.12)	0.06
$40.00	30.32	10.95	(8.73)	2.22
$45.00	30.32	13.10	(8.54)	4.56
$50.00	30.32	14.82	(7.69)	7.13
$55.00	30.32	16.23	(6.99)	9.24
$60.00	30.32	17.40	(6.41)	11.00

Note: This table is for illustrative purposes and does not represent our forecast of future stock performance
1 The prices listed in the table are illustrative. Although dilution continues beyond $60 per share, we have not presented further data
2 Assumes if-converted accounting, excludes offset of capped call (non-GAAP metric)
3 Assumes intent to net share settle convertible notes (treasury stock method accounting); includes offset of capped call (non-GAAP metric)

Footnotes

Share Count and Adjusted Metrics

Share count

239,732,572 shares of Class A common stock were outstanding as of September 30, 2026. This excludes (1) 5,759,555 shares of Class B common stock outstanding as of September 30, 2026, (2) 849,354 shares of Class A common stock underlying restricted stock units, 2,044,860 shares of Class A common stock underlying performance stock units, and 2,500,000 shares of Class A common stock underlying performance stock options; and (3) any other shares issuable from future equity awards under our 2021 Omnibus Incentive Plan, which had 43,253,366 shares reserved (subject to annual automatic increases) as of September 30, 2026. The 5,759,555 shares of Class B common stock are paired on a one-for-one basis with shares of Class B common stock of Mirion Intermediate Co., Inc. (the "paired interests"). Holders of the paired interests have the right to have their interests redeemed for, at the option of Mirion, shares of Class A common stock on a one-for-one basis or cash based on a trailing stock price average. All share data is as of September 30, 2026, unless otherwise noted.

Reconciliation of Non-GAAP Financial Measures

In addition to our results determined in accordance with GAAP, we believe the following non-GAAP measures are useful in evaluating our operating performance. We use the following non-GAAP financial information to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison.

Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures and not rely on any single financial measure to evaluate our business.

Organic revenues is defined as revenues excluding the impact of foreign exchange rates as well as mergers, acquisitions and divestitures in the period.

Adjusted gross profit is defined as gross profit adjusted to exclude the impact of amortization of acquired intangible assets, depreciation, the impact of purchase accounting on the recognition of deferred revenue and certain non-operating expenses (certain purchase accounting impacts related to inventory and costs to achieve operational synergies).

Adjusted EBITDA is defined as net income before interest expense, income tax expense, depreciation and amortization adjusted to remove the impact of foreign currency gains and losses, amortization of acquired intangible assets, changes in the fair value of warrants, certain non-operating expenses (restructuring and costs to achieve operational synergies, merger, acquisition and divestiture expenses and IT project implementation expenses), stock-based compensation expense, debt extinguishment and income tax impacts of these adjustments.

Adjusted net income is defined as GAAP net income adjusted for foreign currency gains and losses, amortization of acquired intangible assets, changes in the fair value of warrants, certain non-operating expenses (restructuring and costs to achieve operational synergies, merger, acquisition and divestiture expenses and IT project implementation expenses), stock-based compensation expense (2025 and prior), debt extinguishment and income tax impacts of these adjustments.

Adjusted EPS is as adjusted net income divided by weighted average common shares outstanding — basic and diluted.

Adjusted free cash flow is defined as free cash flow adjusted to include the impact of cash used to fund non-operating expenses described above. We believe that the inclusion of supplementary adjustments to free cash flow applied in presenting adjusted free cash flow is appropriate to provide additional information to investors about our cash flows that management utilizes on an ongoing basis to assess our ability to generate cash for use in acquisitions and other investing and financing activities.

Adjusted free cash flow conversion is defined as adjusted free cash flow divided by adjusted EBITDA.

Free cash flow is defined as U.S. GAAP net cash provided by operating activities adjusted to include the impact of purchases of property, plant, and equipment, purchases of badges and proceeds from derivative contracts.

Net leverage is defined as net debt (debt minus cash and cash equivalents) divided by Adjusted EBITDA plus contributions to Adjusted EBITDA if acquisitions made during the applicable period had been made before the start of the applicable period.

Operating Metrics

Orders and Order growth are defined as the amount of revenue earned in a given period and estimated to be earned in future periods from contracts entered into in a given period as compared with such amount for a prior period. Foreign exchange rates are based on the applicable rates for the time period.

MIRION